Picture of I-Mab logo

IMAB I-Mab Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-3.42%
3m-2.31%
6m-19.23%
1yr-66.99%
Volume Change (%)
10d/3m-40.58%
Price vs... (%)
52w High-59.73%
50d MA-1.69%
200d MA-12.9%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-63.92%
Return on Equity-69.11%
Operating Margin717.5%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of I-Mab EPS forecast chart

Profile Summary

I-Mab is a China-based company mainly engaged in the development of innovative global biotechnology. The Company's main businesses include engaging in track record in innovation, developing innovative drug candidates and conduct clinical validation of the assets and commercialization. The Company's pipeline is composed of ten clinical-stage assets and ten preclinical assets, among which seven assets have moved to Phase 2 or Phase 3 clinical trial stage. Its pipeline is expected to yield three near-term NDA filings and/or product launches, including felzartamab for multiple myeloma (MM), eftansomatropin alfa for pediatric growth hormone deficiency (PGHD), and potentially lemzoparlimab for myelodysplastic syndromes (MDS) and later for acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL).

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
June 30th, 2016
Public Since
January 17th, 2020
No. of Employees
318
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
190,033,689
Blurred out image of a map
Address
WILLOW HOUSE, Floor 4, SHANGHAI, 200124
Web
https://www.i-mabbiopharma.com/
Phone
+86 2160578000
Auditors
PricewaterhouseCoopers Zhong Tian LLP

IMAB Share Price Performance

Upcoming Events for IMAB

Full Year 2023 I-Mab Earnings Release

Half Year 2024 I-Mab Earnings Release

Similar to IMAB

Picture of 111 logo

111

us flag iconNASDAQ Global Market

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

FAQ